AR024558A1 - COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME - Google Patents

COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME

Info

Publication number
AR024558A1
AR024558A1 ARP000102690A ARP000102690A AR024558A1 AR 024558 A1 AR024558 A1 AR 024558A1 AR P000102690 A ARP000102690 A AR P000102690A AR P000102690 A ARP000102690 A AR P000102690A AR 024558 A1 AR024558 A1 AR 024558A1
Authority
AR
Argentina
Prior art keywords
processes
compositions
produce
same
beta peptide
Prior art date
Application number
ARP000102690A
Other languages
Spanish (es)
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Publication of AR024558A1 publication Critical patent/AR024558A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

Se refiere a procesos para preparar composiciones que comprenden al péptido A beta solubilizado o a suspensiones del péptido A beta ajustando el pH losuficiente como para lograr la solubilizacion, y la filtracion estéril de las mismas, a métodos paratratar de prevenir la enfermedad de Alzheimer con lascomposiciones obtenidas y a procesos para producir las mismas.It refers to processes for preparing compositions comprising the solubilized beta A peptide or suspensions of the beta A peptide by adjusting the pH sufficient to achieve solubilization, and sterile filtration thereof, to methods to try to prevent Alzheimer's disease with the compositions obtained and processes to produce them.

ARP000102690A 1999-06-01 2000-05-31 COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME AR024558A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13704799P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
AR024558A1 true AR024558A1 (en) 2002-10-16

Family

ID=22475602

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102690A AR024558A1 (en) 1999-06-01 2000-05-31 COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME

Country Status (25)

Country Link
EP (1) EP1181040A1 (en)
JP (1) JP2003519620A (en)
KR (1) KR20020016813A (en)
CN (1) CN1353615A (en)
AR (1) AR024558A1 (en)
AU (1) AU5726100A (en)
BG (1) BG106249A (en)
BR (1) BR0011251A (en)
CA (1) CA2374897A1 (en)
CZ (1) CZ20014150A3 (en)
EE (1) EE200100649A (en)
HK (1) HK1045938A1 (en)
HR (1) HRP20010901A2 (en)
IL (1) IL146575A0 (en)
IS (1) IS6182A (en)
MX (1) MXPA01012355A (en)
NO (1) NO20015859L (en)
NZ (1) NZ515744A (en)
PE (1) PE20010212A1 (en)
PL (1) PL352575A1 (en)
RU (1) RU2001135800A (en)
SK (1) SK17012001A3 (en)
TR (1) TR200103476T2 (en)
WO (1) WO2000072870A1 (en)
ZA (1) ZA200109704B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
WO2002025279A2 (en) * 2000-09-19 2002-03-28 Evotec Neurosciences Gmbh Use of amyloid precursor protein for treating brain amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
AR052051A1 (en) 2004-12-15 2007-02-28 Neuralab Ltd AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION
RS53270B2 (en) 2005-11-30 2018-05-31 Abbvie Deutschland Monoclonal antibodies against amyloid beta protein and uses thereof
JP5475994B2 (en) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody.
PL2004688T5 (en) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (en) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
US9573994B2 (en) 2014-07-10 2017-02-21 Bioarctic Neuroscience Ab Aβ protofibril binding antibodies
CN114957438B (en) * 2022-06-28 2024-04-02 福建亿彤生物科技有限公司 Human Abeta 1-42 epitope polypeptide for detecting Alzheimer disease and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016819A1 (en) * 1990-04-27 1991-11-14 Molecular Rx., Inc. Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
HRP20010901A2 (en) 2003-04-30
SK17012001A3 (en) 2002-06-04
EE200100649A (en) 2003-02-17
CZ20014150A3 (en) 2002-05-15
MXPA01012355A (en) 2003-06-24
TR200103476T2 (en) 2002-04-22
WO2000072870A1 (en) 2000-12-07
HK1045938A1 (en) 2002-12-20
BG106249A (en) 2002-08-30
PE20010212A1 (en) 2001-02-22
EP1181040A1 (en) 2002-02-27
PL352575A1 (en) 2003-08-25
RU2001135800A (en) 2003-08-20
CA2374897A1 (en) 2000-12-07
NO20015859D0 (en) 2001-11-30
CN1353615A (en) 2002-06-12
ZA200109704B (en) 2003-02-26
IS6182A (en) 2001-11-29
AU5726100A (en) 2000-12-18
NZ515744A (en) 2004-04-30
JP2003519620A (en) 2003-06-24
BR0011251A (en) 2002-03-05
NO20015859L (en) 2002-02-01
IL146575A0 (en) 2002-07-25
KR20020016813A (en) 2002-03-06

Similar Documents

Publication Publication Date Title
AR024558A1 (en) COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME
DOP2002000429A (en) IMIDAZOTRIAZINAS
ECSP055719A (en) TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
GT199900140A (en) DERIVATIVES OF QUINOLIN-2-ONA ALQUINILS SUBSTITUTED USEFUL AS ANTI-TARGET AGENTS.
BRPI0409611A (en) piperazine derivatives and their use for the treatment of neurological and psychiatric disorders
PT1200105E (en) FACTOR VIII MODIFIED
BRPI0307702B8 (en) antibody-containing solution formulations
BR0017026A (en) Lipeptides as antibacterial agents
DE60037139D1 (en) POLY-HYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND ALPHA-SYNUCLEIN FIBRIL DISEASES
GT199900067A (en) NEW 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURTIC DEDERMATOSIS.
BRPI0407662A (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
ATE311226T1 (en) THE GLYCINE BETAIN FOR ITS ANTITHROMBOTIC USE
DE60318839D1 (en) 2,6-CHINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USES FOR THE TREATMENT OF VLA-4 RELATED DISEASES
MX9305248A (en) DIARILPIPERAZINOACETAMIDA COMPOUNDS.
GT199900154A (en) PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON, ADHD AND MICROADENOMAS DISEASE.
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
DE60015508D1 (en) C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOG
MXPA04005079A (en) Factor viii c2 domain variants.
CY1110644T1 (en) 5,6,7-Trihydroxyheptanoic acid and its analogues for the treatment of ophthalmic diseases related to hypercapillary and angiogenic diseases
DE60016181D1 (en) C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOG
EA200100700A1 (en) GENES AND PROTEINS AND THEIR APPLICATION
DE59610251D1 (en) CONJUGATE, INCLUDING AN ACTIVE SUBSTANCE, A POLYPEPTIDE AND A POLYETHER
BR0315836A (en) [6,7-Dihydro-5h-imidazole [1,2-alpha] imadazol-3-sulfonyl mino] propionamide derivatives, pharmaceutical composition, use thereof, and process for their preparation
UY27451A1 (en) 2,5-DIAMIDOINDOLES REPLACED AND ITS USE
ATE464048T1 (en) TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure